Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab

Eye

Volumn 25, Issue 6, 2011, Pages 661-672

  Meyer, C H ^a   Holz, F G ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

age related macular degeneration; Avastin; bevacizumab; Lucentis; ranibizumab; VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRASTUZUMAB; VASCULOTROPIN; VERTEPORFIN;

CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; EYE DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RETINA CELL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

EID: 79958706138     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.66     Document Type: Review

References (96)

1. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008;2:377-388.
2. Kroll P, Meyer CH. Which treatment is best for which AMD patient? Br J Ophthalmol 2006;90:128-130. (Pubitemid 43163835)
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-2617.
4. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e55.
8. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
9. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S et al. The effects of a flexible visual acuitydriven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010;51:405-412.
10. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870. (Pubitemid 44547437)
11. Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU, Adam A, Shinoda K et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-790. (Pubitemid 351831327)
12. ®) in its binding affinity to retinal pigment epithelium (RPE) and vascular endothelium cell membranes. Invest Ophthalmol Vis Sci 2010;51: E-Abstract 4955.
13. ®). Invest Ophthalmol Vis Sci 2010;51: E-Abstract 4954.
14. Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular agerelated macular degeneration. Retina 2007;27:541-551. (Pubitemid 46905143)
15. Kook D, Wolf A, Neubauer AS, Haritoglou C, Priglinger SG, Kampik A et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe 2008;105:158-164.
16. Avastin. Avastin prescribing information. Available at http://www.avastin. com/avastin/hcp/overview/index.html. Accessed 27 June 2010.
17. Liu L, Ammar DA, Ross L, Mandava N, Kahook M, Carpenter J. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52(2):1023-1034.
18. Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007;91:827-831. (Pubitemid 46846661)
19. Grisanti S, Tura A. Qualitätsunterschiede zwischen ranibizumab original & fertigspritzen. Ophthalmologe 2010;107:1123-1132.
20. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
21. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64.
22. European Medicines Agency. Avastin assessment history, initial marketing authorization documents: Avastin EPAR scientific discussion. Available at http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000582/human-med-000663.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d125. Accessed July 2010.
23. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71. (Pubitemid 26026196)
24. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599. (Pubitemid 27441066)
25. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881. (Pubitemid 29527672)
26. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998;6:1153-1167. (Pubitemid 28434118)
27. Baca M, Presta LG, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997;272:10678-10684. (Pubitemid 27181078)
28. European Medicines Agency. Lucentis assessment history, initial marketing authorization documents: Lucentis EPAR scientific discussion. Available at http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000715/human-med-000890.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d125. Accessed July 2010.
29. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-1182. (Pubitemid 44351153)
30. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518. (Pubitemid 44620391)
31. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230-1233. (Pubitemid 47344905)
32. Cheng CK, Peng PH, Tien LT, Cai YJ, Chen CF, Lee YJ. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina 2009;29:306-312.
33. Brar VS, Sharma RK, Murthy RK, Chalam KV. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. J Ocul Pharmacol Ther 2009;25:507-511.
34. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977-982. (Pubitemid 47329805)
35. Yoeruek E, Tatar O, Spitzer MS, Saygili O, Biedermann T, Bartz-Schmidt KU et al. Effects of bevacizumab on apoptosis, Na+-K+-adenosine triphosphatase and zonula occludens 1 expression on cultured corneal endothelial cells. Ophthalmic Res 2010;44:43-49.
36. Han YS, Lee JE, Jung JW, Lee JS. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:541-548.
37. Sharma RK, Chalam KV. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol 2009;87:618-622.
38. Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L et al. Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem 2009;108:1410-1417.
39. Deissler H, Deissler H, Lang S, Lang GE. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008;92:839-843. (Pubitemid 351839580)
40. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19:437-441.
41. Miura Y, Klettner A, Roider J. VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro - possible participation of intracellular glutathione. Invest Ophthalmol Vis Sci 2010;51:4848-4855.
42. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009;247:1601-1608.
43. Klettner A, Mohle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 2010;248:819-824.
44. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182. (Pubitemid 350181137)
45. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859. (Pubitemid 46635858)
46. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266. (Pubitemid 350211535)
47. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733. (Pubitemid 40270359)
48. Thaler S, Fiedorowicz M, Choragiewicz TJ, Bolz S, Tura A, Henke-Fahle S et al. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol 2010;88: e170-e176.
49. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-2812.
50. Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010;51:3701-3708.
51. Dib E, Maia M, Longo-Maugeri IM, Martins MC, Mussalem JS, Squaiella CC et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 2008;49:1097-1100.
52. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-4813.
53. Byeon SH, Kang SY. Pharmacokinetics. Ophthalmology 2009;116:168-169; author reply 169-170.
54. Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 2009;116:1748-1754.
55. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542. (Pubitemid 44748725)
56. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-874.
57. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
58. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-1739.
59. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399.
60. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Retina 2010;30:1034-1038.
61. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-786.
62. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26:871-876. (Pubitemid 44547438)
63. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
64. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28:1308-1313.
65. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-1755, 1755 e1751.
66. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
67. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 vs 1.25mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29:319-324.
68. Meyer C, Krohne T, Holz F. Intraocular pharmacokinetics after single intravitreal injection of 1.5 vs 3.0 mg bevacizumab in humans. Retina 2011 (In Press).
69. Wang JJ, Mitchell P, Smith W, Cumming RG, Attebo K. Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999;40:12-19. (Pubitemid 29029566)
70. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007;27:1196-1200. (Pubitemid 350211524)
71. Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93:1027-1032.
72. Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009;29:1067-1073.
73. Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina 2009;29:1235-1241.
74. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E et al. Bevacizumab vs ranibizumab for agerelated macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009;148:875-882 e871.
75. Subramanian ML, Abedi G, Ness S, Feinberg E, Fenberg MJ, Daly M et al. Bevacizumab vs ranibizumab: one year outcomes of a head-to-head, prospective, double-masked, randomized clinical trial. Invest Ophthalmol Vis Sci 2010;51: E-Abstract 517.
76. Kent JS, Iordanous Y, Mao A, Shukla S, Sheidow TG. Comparison of outcomes when switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51: E-Abstract 82.
77. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z et al. Avastin (Bevacizumab) for choroidal neovascularisation in age-related macular degeneration (ABC) trial. BMJ 2010;340: c2459.
78. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol; doi:10.1136/bjo.2010.180729.
79. Meyer CH, Krohne TU, Holz FG. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol; doi:10.1111/j.1755-3768.2009.01842.x.
80. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1379-1381.
81. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51:1606-1608.
82. Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers III MB, Morales-Caton V, Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 2009;29:20-26.
83. Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. Br J Ophthalmol 2009;93:914-919.
84. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008;37:591-593.
85. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215-1218.
86. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 2010;88: e136.
87. Yoon YH, Kim JG, Chung H, Lee SY. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Acta Ophthalmol 2009;87:685-687.
88. Mennel S, Callizo J, Schmidt JC, Meyer CH. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 2007;85:689-691. (Pubitemid 47316777)
89. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136. (Pubitemid 351398487)
90. Novartis. Lucentis prescribing information. 2006.
91. Gamulescu MA, Helbig H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 2010;26:213-216.
92. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 2010;149:939-946 e931.
93. Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009;223:383-389.
94. Schmidt-Erfurth U. Clinical safety of ranibizumab in agerelated macular degeneration. Expert Opin Drug Saf 2010;9:149-165.
95. USP 28/NF 23. Chapter <7894 >Particulate matter in ophthalmic solutions'. In: United States Pharmacopeial Convention, Inc: Rockville, MD, 2005.
96. USP 28/NF 23. Chapter <7884 >Particulate matter in injections'. In: United States Pharmacopeial Convention, Inc: Rockville, MD, 2005.